Skip to content
Article Rich – Lifestyle
Author:
Dogwood Therapeutics, Inc.
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
June 30, 2026
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
May 21, 2026
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
May 7, 2026
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
April 23, 2026
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
April 15, 2026
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 18, 2026